frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD

Diffuse large B-cell lymphoma (DLBCL) remains a disease with a significant unmet need, particularly among patients with high-intermediate or high-risk disease. Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the established standard of care, roughly 40% of patients still fail this regimen, according to the phase 3 frontMIND trial (NCT04824092) investigators.

The frontMIND trial sought to address this gap by adding tafasitamab, a CD19-directed monoclonal antibody designed to enhance natural killer cell activity, and lenalidomide to R-CHOP. At the European Hematology Association 2026 Congress in Stockholm, Sweden, the trial results were presented this afternoon during the plenary abstracts session by lead investigator Georg Lenz, MD. Ahead of the session, The American Journal of Managed Care^® spoke with Umberto Vitolo, MD, a frontMIND investigator, about the findings and their significance.

The global, phase 3, double-blind, placebo-controlled trial enrolled 899 patients aged 18 to 80 years with previously untreated high-intermediate- or high-risk DLBCL or high-grade B-cell lymphoma. Patients were randomized 1:1 to receive tafasitamab plus lenalidomide and R-CHOP (Tafa-Len-R-CHOP) or R-CHOP alone.

At a median follow-up of 35.2 months, the trial met its primary end point: Tafa-Len-R-CHOP produced a statistically significant 25% reduction in the risk of disease progression or death compared with R-CHOP, with 24-month progression-free survival (PFS) rates of 71.1% vs 62.9%. Vitolo emphasized that even without mature overall survival data, the observed PFS benefit carries meaningful clinical weight.

He noted that relapse typically requires second-line therapies such as chimeric antigen receptor T-cell (CAR T) therapy or bispecific antibodies, which, while effective, represent a substantial treatment burden. End-of-treatment positron emission tomography-negative complete response rates were similar between arms, a pattern that Vitolo noted has appeared in other studies. However, he highlighted that data to be presented separately at the meeting by Lenz on measurable residual disease monitoring showed significantly deeper molecular responses in the experimental arm, which may help explain the PFS advantage.

Regarding the safety profile, grade 3 or higher treatment-emergent adverse events occurred more frequently with Tafa-Len-R-CHOP, driven largely by neutropenia and a modest increase in infections. Importantly, R-CHOP dose intensity was maintained equally across both arms, and discontinuation rates were nearly identical, which, Vitolo explained, confirms that the added toxicity was manageable without compromising delivery of the chemotherapy backbone.

He also highlighted consistent PFS benefit across activated B-cell-like and germinal center B-cell-like molecular subtypes, as well as in double-hit patients, supporting Tafa-Len-R-CHOP as a potential new first-line standard of care for high-risk DLBCL regardless of cell-of-origin subtype.

“I think that if we expand our treatment options in [DLBCL], it’s good news for the patient,” he concluded.